The 12 most recent market catalysts affecting $TAK, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 14, 2026
Corporate Catalyst
Bullish
Impact 75
Earlier on Monday, FDA Accepted Takeda's Application Under Priority Review for Zasocitinib (TAK-279) For Moderate-To-Severe Plaque Psoriasis, With PDUFA Action Date in Q1 2027
The FDA granting priority review for Takeda's Zasocitinib is a significant positive catalyst for the company. Priority review shortens the FDA's review period, indicating the agenc…
Sep 14, 2026
Corporate Catalyst
Bullish
Impact 75
Takeda's Zasocitinib Shows About 70% Of Patients Achieving Clear Or Almost Clear Skin At Week 16 In Phase 3 LATITUDE PsO Studies Of Nearly 3,000 Patients
Takeda has announced highly positive Phase 3 clinical trial results for Zasocitinib, its oral TYK2 inhibitor for psoriasis. The data, showing approximately 70% of patients achievin…
Sep 9, 2026
Corporate Catalyst
Bullish
Impact 75
Takeda's Phase 3 Trial Of Oveporexton's Data Published In New England Journal Of Medicine To Treat Narcolepsy Type 1; Oveporexton Generally Well-Tolerated With Consistent Safety Profile
Takeda announced that the New England Journal of Medicine published positive Phase 3 trial results for oveporexton, an oral orexin receptor 2 agonist, in treating narcolepsy type 1…
Aug 31, 2026
Corporate Catalyst
Bullish
Impact 85
Takeda Secures FDA Approval For First-In-Class Blood Cancer Drug
The FDA approval of MIMRYLO for polycythemia vera is a major positive for Takeda, as it introduces a first-in-class drug into the market for a serious blood cancer. This approval v…
Aug 13, 2026
Corporate Catalyst
Neutral
Impact 55
Vinod Khosla Says AI Is Creating a ‘Hyperabundance’ of New Drugs, but Testing Is Still ‘18th-Century’
This filing discloses Vinod Khosla's perspective on the evolving landscape of drug discovery, emphasizing the transformative power of AI in generating new drug candidates. The core…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 85
Takeda Achieves Major Milestone With Holistic Narcolepsy Drug Approval
Takeda Pharmaceutical Co. Ltd. (TAK) announced FDA approval for its new drug, Orzeyful, for narcolepsy type 1. This is a major positive catalyst for Takeda as Orzeyful is a first-i…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 85
Takeda's ORZEYFUL Wins FDA Approval As First Orexin Therapy For Narcolepsy Type 1; U.S. Launch Planned Following DEA Scheduling
Takeda has received FDA approval for ORZEYFUL, an oral orexin receptor 2 agonist, for the treatment of narcolepsy type 1 (NT1). This is a significant event as ORZEYFUL is a 'first-…
Jul 30, 2026
Corporate Catalyst
Bearish
Impact 75
Takeda Pharmaceutical Co Lowers FY2026 Adj EPS Guidance from $3.01 to $2.96 vs $1.57 Est; Lowers FY2026 Sales Guidance from $29.585B to $29.116B vs $28.950B Est
Takeda Pharmaceutical Co (TAK) has announced a reduction in its fiscal year 2026 adjusted EPS guidance from $3.01 to $2.96 and its sales outlook from $29.585 billion to $29.116 bil…
Jul 30, 2026
Corporate Catalyst
Bearish
Impact 85
Takeda Pharmaceutical Q1 Adj. EPS $0.48 Beats $0.39 Estimate, Sales $7.655B Beat $7.060B Estimate
Takeda Pharmaceutical (TAK) announced its Q1 earnings, reporting adjusted EPS of $0.48, significantly beating the $0.39 consensus estimate, and sales of $7.655 billion, also surpas…
Jul 17, 2026
Corporate Catalyst
Bullish
Impact 75
Oral Psoriasis Drug From Takeda Demonstrates Strong Skin Clearance in Trials
Takeda Pharmaceutical released encouraging secondary data for its oral psoriasis drug, zasocitinib, from two pivotal Phase 3 trials. The drug showed significant skin clearance in c…
Jul 17, 2026
Corporate Catalyst
Bullish
Impact 85
Takeda shares are trading higher after the company announced that Phase 3 data from two studies of Zasocitinib in adults with plaque psoriasis indicate consistent and high skin clearance rates.
This headline represents a strong positive corporate catalyst for Takeda. Successful Phase 3 trials are crucial for drug development, indicating a high probability of regulatory ap…
Jul 17, 2026
Corporate Catalyst
Bullish
Impact 75
Reported July 16: Takeda Announces New Data From Two Phase 3 Studies Of Zasocitinib In Adults With Plaque Psoriasis; Secondary Endpoint Data Indicate Consistent And High Rates Of Skin Clearance
Takeda has released new, positive secondary endpoint data from its Phase 3 studies for zasocitinib, a TYK2 inhibitor for plaque psoriasis. The data highlights the drug's effectiven…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.